KALARIS THERAPEUTICS, INC. (KLRS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $240.11M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-73.00K; Retained Earnings (Accumulated Deficit)USD $-182.37M.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $239.46M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-49.00K; Retained Earnings (Accumulated Deficit)USD $-170.85M.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $238.81M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K; Retained Earnings (Accumulated Deficit)USD $-160.00M.
- 2025-09-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $191.86M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.00K; Retained Earnings (Accumulated Deficit)USD $-150.00M.
KALARIS THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00K | $240.11M | $-73.00K | $-182.37M | $57.67M | (m) | 3 month · $644.00K |
| 2026-03-31 | $2.00K | $239.46M | $-49.00K | $-170.85M | $68.56M | (m) | 3 month · $580.00K |
| 2025-12-31 | $2.00K | $238.81M | $6.00K | $-160.00M | $78.81M | 12 month · $5.36M | 12 month · $1.94M |
| 2025-09-30 | $2.00K | $191.86M | $6.00K | $-150.00M | $41.87M | (m) | 3 month · $638.00K |
| 2025-06-30 | $2.00K | $191.22M | (m) | $-138.11M | $53.12M | (m) | 3 month · $591.00K |
| 2025-03-31 | $2.00K | $190.63M | (m) | $-126.76M | $63.87M | 3 month · $5.36M | 3 month · $374.00K |
| 2024-12-31 | $0.00 | $19.95M | $0.00 | $-116.56M | $-96.62M | (m) | 12 month · $895.00K |
| 2024-09-30 | $11.00K | $817.93M | $-134.00K | $-696.69M | $-89.38M | (m) | 3 month · $262.00K |
| 2024-06-30 | $11.00K | $812.99M | $-139.00K | $-692.57M | $-51.53M | (m) | 3 month · $322.00K |
| 2024-03-31 | $11.00K | $807.06M | $-138.00K | $-686.49M | $-47.54M | (m) | 3 month · $31.00K |
| 2023-12-31 | $0.00 | $802.04M | $-62.00K | $-656.19M | $-45.02M | (m) | 12 month · $40.78M |
| 2023-09-30 | $11.00K | $792.02M | $-200.00K | $-596.50M | $195.33M | (m) | 3 month · $10.47M |
| 2023-06-30 | $11.00K | $781.55M | $-225.00K | $-552.23M | $229.11M | (m) | 3 month · $10.29M |
| 2023-03-31 | $9.00K | $700.78M | $-301.00K | $-506.96M | $193.53M | (m) | 3 month · $10.03M |
| 2022-12-31 | $9.00K | $690.75M | $-468.00K | $-465.77M | $224.52M | 12 month · $200.00K | 12 month · $41.31M |
| 2022-09-30 | $9.00K | $681.42M | $-563.00K | $-427.64M | $253.23M | 3 month · $200.00K | 3 month · $10.86M |
| 2022-06-30 | $7.00K | $544.14M | $-444.00K | $-385.57M | $158.14M | (m) | 3 month · $10.95M |
| 2022-03-31 | $7.00K | $532.95M | $-350.00K | $-385.60M | $191.68M | (m) | 3 month · $10.47M |
| 2021-12-31 | $7.00K | $522.48M | $-155.00K | $-297.06M | $225.27M | (m) | 12 month · $43.98M |
| 2021-09-30 | $7.00K | $506.55M | $-133.00K | $-239.12M | $267.30M | (m) | 3 month · $10.29M |
| 2021-06-30 | $7.00K | $496.10M | $-25.00K | $-193.61M | $302.47M | (m) | 3 month · $9.73M |
| 2021-03-31 | $7.00K | $486.38M | $13.00K | $-156.03M | $330.37M | (m) | 3 month · $8.10M |
| 2020-12-31 | $7.00K | $478.27M | $-112.00K | $-125.10M | $353.06M | (m) | 12 month · $9.43M |
| 2020-09-30 | $7.00K | $473.84M | $-41.00K | $-99.90M | $373.90M | (m) | 3 month · $3.86M |
| 2020-06-30 | (m) | $4.89M | $110.00K | $-76.29M | $-71.29M | (m) | 3 month · $492.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-60.02M | (m) | 3 month · $646.00K |
| 2019-12-31 | (m) | $3.75M | $68.00K | $-55.32M | $-51.50M | (m) | 12 month · $2.89M |
| 2019-09-30 | (m) | (m) | (m) | (m) | $-43.35M | (m) | 3 month · $596.00K |
| 2019-06-30 | (m) | (m) | (m) | (m) | $-36.65M | (m) | 3 month · $1.44M |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-32.91M | (m) | 3 month · $231.00K |
| 2018-12-31 | (m) | (m) | (m) | (m) | $-30.62M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |